

# Maya H Buch

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6684185/maya-h-buch-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130  
papers

7,818  
citations

34  
h-index

87  
g-index

155  
ext. papers

10,205  
ext. citations

5.4  
avg, IF

5.67  
L-index

#	Paper	IF	Citations
130	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 492-509	3.4	1487
129	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 964-75	2.4	1210
128	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 685-699	3.4	851
127	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 62-8	2.4	467
126	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 909-20	2.4	308
125	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 529-35	2.4	266
124	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 516-28	2.4	224
123	B cell biomarkers of rituximab responses in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 3038-47		156
122	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 326, 499-518	27.4	154
121	Sustained remission with etanercept tapering in early rheumatoid arthritis. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1781-92	59.2	141
120	Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. <i>Blood</i> , <b>2002</b> , 100, 4550-6	2.2	127
119	Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 2287-91	4.1	123
118	Drug-Induced Interstitial Lung Disease: A Systematic Review. <i>Journal of Clinical Medicine</i> , <b>2018</b> , 7,	5.1	117
117	Synovial tissue research: a state-of-the-art review. <i>Nature Reviews Rheumatology</i> , <b>2017</b> , 13, 463-475	8.1	107
116	Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 510-5	2.4	106
115	BSR and BHPR guideline for the treatment of systemic sclerosis. <i>Rheumatology</i> , <b>2016</b> , 55, 1906-10	3.9	97
114	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1207-1218	2.4	71

113	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial		65
112	Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1405-1412	2.4	63
111	Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 725-8		63
110	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 31-35	2.4	61
109	Defining refractory rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 966-969	2.4	58
108	Anti-TNF treatment in rheumatoid arthritis. <i>Current Pharmaceutical Design</i> , <b>2011</b> , 17, 3141-54	3.3	55
107	New therapies in the management of rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , <b>2011</b> , 23, 245-51	5.3	54
106	Reporting of long-term extension studies: lack of consistency calls for consensus. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 886-90	2.4	52
105	Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. <i>Rheumatology</i> , <b>2017</b> , 56, 912-921	3.9	47
104	TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes. <i>Journal of Autoimmunity</i> , <b>2014</b> , 50, 59-66	15.5	45
103	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , <b>2021</b> , 397, 305-317	4.0	42
102	Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1812-1823	9.5	40
101	A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud® Phenomenon. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 903-911	9.5	39
100	Biologics registers in RA: methodological aspects, current role and future applications. <i>Nature Reviews Rheumatology</i> , <b>2017</b> , 13, 503-510	8.1	37
99	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial		37
98	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , <b>2018</b> , 57, 370-381	3.9	36
97	An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1195-201	2.4	34
96	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1553-1570	9.5	31

95	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 563-570	2.4	31
94	Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 239	5.7	30
93	Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 909-12	2.4	30
92	Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 17-33	8.1	29
91	The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 420-7	2.4	28
90	The role of non-invasive cardiovascular imaging in the assessment of cardiovascular risk in rheumatoid arthritis: where we are and where we need to be. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1169-1175	2.4	27
89	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 963-9	2.4	27
88	Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy. <i>Rheumatology</i> , <b>2016</b> , 55, 1177-87	3.9	27
87	Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 288	5.7	27
86	Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy. <i>Frontiers in Medicine</i> , <b>2019</b> , 6, 45	4.9	23
85	Sequential use of biologic therapy in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , <b>2010</b> , 22, 321-9	5.3	22
84	Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. <i>Rheumatology</i> , <b>2019</b> ,	3.9	21
83	Costimulation blockade in rheumatic diseases: where we are?. <i>Current Opinion in Rheumatology</i> , <b>2009</b> , 21, 244-50	5.3	21
82	Biomarkers in the management of scleroderma: an update. <i>Current Rheumatology Reports</i> , <b>2011</b> , 13, 4-12	4.9	20
81	The SwitchQ study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. <i>BMC Musculoskeletal Disorders</i> , <b>2014</b> , 15, 452	2.8	19
80	Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe. <i>RMD Open</i> , <b>2018</b> , 4, e000799	5.9	19
79	Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study. <i>Rheumatology</i> , <b>2016</b> , 55, 2181-2190	3.9	18
78	Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. <i>RMD Open</i> , <b>2018</b> , 4, e000757	5.9	18

77	Incidental significant arrhythmia in scleroderma associates with cardiac magnetic resonance measure of fibrosis and hs-TnI and NT-proBNP. <i>Rheumatology</i> , <b>2019</b> , 58, 1221-1226	3.9	17
76	Ultrasound-detectable grey scale synovitis predicts future fulfilment of the 2010 ACR/EULAR RA classification criteria in patients with new-onset undifferentiated arthritis. <i>RMD Open</i> , <b>2017</b> , 3, e000394	5.9	16
75	After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?. <i>Postgraduate Medical Journal</i> , <b>2012</b> , 88, 482-6	2	16
74	Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 4072-3		16
73	To switch or not to switch after a poor response to a TNF blocker? It is not only a matter of ACR20 OR ACR50. <i>Autoimmunity Reviews</i> , <b>2012</b> , 11, 558-62	13.6	15
72	Relationship between early bone mineral density changes and long-term function and radiographic progression in rheumatoid arthritis. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 66-70	4.7	15
71	Transforming clinical trials in rheumatology: towards patient-centric precision medicine. <i>Nature Reviews Rheumatology</i> , <b>2020</b> , 16, 590-599	8.1	15
70	The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. <i>Rheumatology</i> , <b>2014</b> , 53, 1344-6	3.9	14
69	Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 463-4	2.4	14
68	Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1414-1422	2.4	14
67	Foot health needs in people with systemic sclerosis: an audit of foot health care provision. <i>Clinical Rheumatology</i> , <b>2011</b> , 30, 1611-5	3.9	13
66	Primary myocardial disease in scleroderma-a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group. <i>Rheumatology</i> , <b>2017</b> , 56, 882-895	3.9	13
65	Coronary Artery Disease Evaluation in Rheumatoid Arthritis (CADERA): study protocol for a randomized controlled trial. <i>Trials</i> , <b>2014</b> , 15, 436	2.8	12
64	Creative trial design in RA: optimizing patient outcomes. <i>Nature Reviews Rheumatology</i> , <b>2013</b> , 9, 183-94	8.1	12
63	B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. <i>Current Rheumatology Reports</i> , <b>2015</b> , 17, 65	4.9	11
62	Absence of Scleroderma pattern at nail fold capillaroscopy valuable in the exclusion of Scleroderma in unselected patients with Raynaud's Phenomenon. <i>BMC Musculoskeletal Disorders</i> , <b>2016</b> , 17, 342	2.8	11
61	Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidance. <i>Clinical Rheumatology</i> , <b>2012</b> , 31, 1005-12	3.9	11
60	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial		11

59	Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial		11
58	Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. <i>Arthritis Research and Therapy</i> , <b>2019</b> , <i>21</i> , 130	5.7	10
57	Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach. <i>Drugs</i> , <b>2020</b> , <i>80</i> , 849-857	12.1	10
56	Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , <i>79</i> , 464-471	2.4	10
55	Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study. <i>RMD Open</i> , <b>2020</b> , <i>6</i> ,	5.9	9
54	Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease. <i>RMD Open</i> , <b>2020</b> , <i>6</i> ,	5.9	9
53	Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY. <i>Rheumatology</i> , <b>2021</b> , <i>60</i> , 3209-3221	3.9	8
52	Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , <i>17</i> , 697-708	4.1	8
51	Normal values and test-retest variability of stimulated-echo diffusion tensor imaging and fat fraction measurements in the muscle. <i>British Journal of Radiology</i> , <b>2019</b> , <i>92</i> , 20190143	3.4	8
50	Nonresponse to tumor necrosis factor antagonists--is there any point in re-treatment?. <i>Nature Clinical Practice Rheumatology</i> , <b>2006</b> , <i>2</i> , 288-9		8
49	A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA). <i>BMC Musculoskeletal Disorders</i> , <b>2016</b> , <i>17</i> , 61	2.8	8
48	The Relationship Between Synovial Pathobiology and Magnetic Resonance Imaging Abnormalities in Rheumatoid Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , <b>2017</b> , <i>44</i> , 1311-1324	4.1	7
47	Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. <i>Health Technology Assessment</i> , <b>2018</b> , <i>22</i> , 1-280	4.4	7
46	Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway. <i>Rheumatology</i> , <b>2021</b> , <i>60</i> , 4048-4054	3.9	7
45	European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. <i>Rheumatology</i> , <b>2019</b> , <i>58</i> , 254-259	3.9	7
44	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	6
43	Syndemics & syndemogenesis in COVID-19 and rheumatic and musculoskeletal diseases: old challenges, new era. <i>Rheumatology</i> , <b>2021</b> , <i>60</i> , 2040-2045	3.9	6
42	Abatacept reduces disease activity and ultrasound power Doppler in ACPA-negative undifferentiated arthritis: a proof-of-concept clinical and imaging study. <i>Rheumatology</i> , <b>2017</b> , <i>56</i> , 58-67	3.9	5

41	First cardiovascular MRI study in individuals at risk of rheumatoid arthritis detects abnormal aortic stiffness suggesting an anti-citrullinated peptide antibody-mediated role for accelerated atherosclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1138-1140	2.4	5
40	Safety of biologics in rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , <b>2012</b> , 7, 425-451	5	5
39	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2022</b> , 7, 24-32	2.3	5
38	Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	5
37	Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial		5
36	Cardiovascular MRI evidence of reduced systolic function and reduced LV mass in rheumatoid arthritis: impact of disease phenotype. <i>International Journal of Cardiovascular Imaging</i> , <b>2020</b> , 36, 491-501	2.5	4
35	Towards an optimum strategy in rheumatoid arthritis. <i>Lancet, The</i> , <b>2012</b> , 379, 1682-4	4.0	4
34	Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations. <i>Drug, Healthcare and Patient Safety</i> , <b>2010</b> , 2, 101-19	1.6	4
33	The perpetual sword of Damocles: Cardiac involvement in systemic sclerosis and the role of non-invasive imaging modalities in medical decision making. <i>European Journal of Rheumatology</i> , <b>2020</b> , 7, S203-S211	1.7	4
32	Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial		4
31	Abnormal electrophysiological testing associates with future incidental significant arrhythmia in scleroderma. <i>Rheumatology</i> , <b>2020</b> , 59, 899-900	3.9	4
30	Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis. <i>Rheumatology</i> , <b>2021</b> , 60, 2934-2945	3.9	4
29	Carotid artery volumetric measures associate with clinical ten-year cardiovascular (CV) risk scores and individual traditional CV risk factors in rheumatoid arthritis; a carotid-MRI feasibility study. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 266	5.7	4
28	Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis. <i>Rheumatology</i> , <b>2019</b> , 58, 1684-1686	3.9	3
27	Response to Correspondence to viewpoint Defining refractory rheumatoid arthritis by Buchby Roodenrijs. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, e106	2.4	3
26	Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
25	Muscle deterioration due to rheumatoid arthritis: assessment by quantitative MRI and strength testing. <i>Rheumatology</i> , <b>2021</b> , 60, 1216-1225	3.9	3
24	Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis. <i>Rheumatology</i> , <b>2021</b> , 60, 3679-3688	3.9	3

23	GP2015 as a promising therapy for rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 477-481	5.4	2
22	Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol. <i>BMJ Open</i> , <b>2021</b> , 11, e044765	3	2
21	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , <b>2021</b> , 6, 66-76	2.3	2
20	Changes in the pharmacological management of rheumatoid arthritis over two decades. <i>Rheumatology</i> , <b>2021</b> , 60, 4141-4151	3.9	2
19	Efficacy and safety of filgotinib in methotrexate-naïve patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	2
18	089 Single centre cohort of refractory rheumatoid arthritis also identifies a rare subgroup of multiple targeted therapy class non-response. <i>Rheumatology</i> , <b>2019</b> , 58,	3.9	1
17	Does high-dose extended course cyclophosphamide and methylprednisolone pulse therapy have a role in the management of systemic sclerosis-related interstitial lung disease?. <i>Rheumatology</i> , <b>2016</b> , 55, 2273-2275	3.9	1
16	The therapeutic window and treating to target in rheumatoid arthritis. <i>Clinical Medicine</i> , <b>2013</b> , 13, 387-90		1
15	Symptom experience of limited cutaneous systemic sclerosis from the Patients perspective: A qualitative study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 52, 151926-151926	5.3	1
14	Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, e140	2.4	1
13	The PREDictor of MALnutrition in Systemic Sclerosis (PREMASS) Score: A Combined Index to Predict 12 Months Onset of Malnutrition in Systemic Sclerosis. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 651748	4.9	1
12	Cardiac magnetic resonance imaging for the detection of myocardial involvement in granulomatosis with polyangiitis. <i>International Journal of Cardiovascular Imaging</i> , <b>2021</b> , 37, 1053-1062	2.5	1
11	Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/double-stranded DNA autoantibody conversion? An analysis of the AMPLE and ATTEST trials. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 127-132	2.2	1
10	Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study.. <i>Clinical Rheumatology</i> , <b>2022</b> , 1	3.9	1
9	Feasibility of MRI based extracellular volume fraction and partition coefficient measurements in thigh muscle. <i>British Journal of Radiology</i> , <b>2020</b> , 93, 20190931	3.4	0
8	RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients.. <i>Scientific Data</i> , <b>2022</b> , 9, 196	8.2	0
7	Response to Dr Bredemeier letter. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, e34	2.4	
6	A1.52 TLR-Dependent XBP1 activation induces an autocrine loop in rheumatoid arthritis synovial fibroblasts. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, A22.1-A22	2.4	



- 5 Use of gevokizumab for the treatment of Behçet disease. *Expert Opinion on Orphan Drugs*, **2013**, 1, 755-763 1.1
- 4 Advances in the development and application of biological therapies for rheumatoid arthritis: review of the latest clinical evidence. *Clinical Investigation*, **2011**, 1, 557-573
- 3 Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study. *Blood*, **2010**, 116, 2322-2322 2.2
- 2 Using cardiovascular magnetic resonance to define mechanisms of comorbidity and to measure the effect of biological therapy: the CADERA observational study. *Efficacy and Mechanism Evaluation*, **2021**, 8, 1-42 1.7
- 1 Response to: Correspondence on Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naive, early rheumatoid arthritis by Georgiadis. *Annals of the Rheumatic Diseases*, **2021**, 2.4